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Purpose: This study was performed to determine the primary patency, foot salvage, and 
complication rates associated with iliac artery stent deployment. 
Methods: From March 1992 to May 1995, 147 iliac artery stents were deployed in 98 limbs 
of 72 patients for disabling claudication or limb-threatening ischemia. Procedure-related 
and late (>30 days) complications, as well as adjunctive maneuvers equired to correct a 
complication, were tabulated. Stented lilac artery cumulative primary patency and foot 
salvage rates were calculated with life-table analysis. Factors that impacted early compli- 
cations, late complications, foot salvage rates, and stented iliac artery primary patency rates 
were identified with stepwise logistic regression analysis. 
Results: A procedure-related complication occurred in 19 (19.4%) limbs. Initial technical 
success, however, was achieved in all but three of 98 limbs (96.9%). Stented iliac artery 
cumulative primary patency rates were 87.6%, 61.9%, 55.3%, and foot salvage rates were 
97.7%, 85.1%, 76.1%, at 12, 18, and 24 months, respectively. External iliac artery stent 
deployment, superficial femoral artery occlusion before treatment, and single-vessel tibial 
runoff before treatment egatively affected stented iliac artery cumulative primary patency 
rates. Stented iliac artery primary patency rates were not significantly affected by age, 
smoking, coronary artery disease, diabetes, hypercholesterolemia, hypertension, present- 
ing symptom, early complication, umber of stents deployed, type of stent deployed, or 
stent deployment for stenosis versus occlusion. 
Conclusions: Limb-threatening and life-threatening complications can be associated with 
iliac artery stent deployment. Stented iliac artery primary patency rates are affected by distal 
atherosclerotic o clusive disease and the position of the deployed stent within the iliac 
system. Steut reconstruction fsevere iliac artery occlusive disease is feasible but should be 
thoughtfully selected. (J Vase Surg 1996;24:545-55.) 
The field of peripheral vascular surgery was 
changed significantly in 1987 by the landmark pub- 
lication of Sigwart ct al., 1 which described the first 
use of  metallic stents in the peripheral arterial cir- 
culation in human beings. Their modest aim was to 
prevent rcstenosis and acute thrombosis of diseased 
peripheral arteries after percutaneous transluminal 
balloon angioplasty was performed. This conserva- 
tive approach began with the placement of 10 pe- 
ripheral stents in six patients. Since that beginning, 
the widespread application of endovascular prosthe- 
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ses for a growing list of  indications has been nothing 
short of remarkable. 
Data accumulated since 1987 suggest hat stent 
deployment in iliac arteries is a safe and effective treat- 
ment for atherosclerotic disease.2-13 Clinical improve- 
ment and iliac artery patency rates, as reported, have 
challenged conventional vascular surgery in the treat- 
ment ofaortoiliac occlusive disease. However, despite 
the belief that iliac artery stent deployment is a benign 
procedure, reported procedure-related failure and 
complication rates range from 7.9% to 23.7%. 2qs Ac- 
tually, the early failure and complication rate is higher 
because some serial complications relating to the same 
stented iliac artery have been tabulated only once, 
some complications have not been tabulated at all, 
and some procedure failures have not been tabulated 
on an "intent-to-treat" basis. 3-s,z,s,l°,ls 
The purpose of our report is not to condemn the 
use ofiliac artery stents. Iliac artery stent deployment 
for severe atherosclerotic o clusive disease has indica- 
tions and merit. Rather, this report focuses on the 
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realities of iliac artery stent deployment and the 
dilemma created by a failed stented iliac artery. 
Factors that have an impact on early and late compli- 
cations, limb loss rates, and stented iliac artery pa- 
tency rates also are discussed. 
PATIENTS AND METHODS 
Between March 10, 1992, and May 2, 1995, 147 
iliac artery stents were deployed in 98 limbs in 72 
patients who had severe aortoiliac occlusive disease. 
The treated extremity had either severe claudication 
(52 limbs, 53.1%), rest pain (21 limbs, 21.4%), 
nonhealing ulceration (16 limbs, 16.3%), or focal 
pedal gangrene (9 limbs, 9.2%). The mean anlde- 
brachial index (ABI) before treatment was 0.34 
(range, 0 to 0.69). No femoral pulse was palpable in 
51 extremities (52%) before treatment, whereas the 
femoral pulse was present in 47 limbs (48%). A 
popliteal pulse was palpable in 12 limbs (12.2%), and 
a pedal pulse was palpable in only 10 limbs (10.2%). 
Associated medical problems included hypertension 
in 54 patients (75.0%), coronary artery disease in 48 
patients (66.7%), hypercholesterolemia in 27 patients 
(37.5%), and diabetes in 18 patients (25.0%). A 
history ofsmoldng was noted in 18 patients (25.0%), 
whereas 41 patients (56.9%) were present smokers. 
Thirteen patients (18.1%) had never smoked. The 
average patient age was 65 years (range, 35 to 87 
years). 
The arteriographic site of treated atherosclerotic 
disease was the common iliac artery in 40 limbs 
(40.8%), the external i iac artery in 19 limbs (19.4%), 
or a combination of the common and external i iac 
arteries in 39 limbs (39.8%). Sixty-five hemodynami- 
cally significant iliac artery stenoses (resting systolic 
pressure gradient_>15 mm Hg; 66.3%) and 33 iliac 
artery occlusions (33.7%) were entered into this 
study. The ipsilateral superficial femoral artery was 
documented by arteriographic examination to be 
widely patent or bypassed (57 limbs, 58.2%), stenotic 
(14 limbs, 14.3%), or occluded (27 limbs, 27.6%) 
before iliac artery stent deployment. Three-vessel 
runoff distal to the ipsilateral popliteal artery was 
present in 44 limbs (44.9%). Two-vessel runoff was 
demonstrated in 28 limbs (28.6%), whereas one- 
vessel runoffwas observed in 26 limbs (26.5%). 
Self-expandable Wallstents (Schneider Inc., Min- 
neapolis, Minn.) were deployed in 49 iliac arteries 
(50%), whereas balloon-expandable Palmaz stents 
(Johnson & Johnson Interventional Systems, Warren, 
N.J.) were deployed in 42 iliac arteries (42.9%). A 
combination of a Wallstent and a Palmaz stent was 
used in seven iliac arteries (7.1%). In most patients, 
either one stent (63 limbs, 64.3%) or two stents (25 
limbs, 25.5%) were deployed uring the procedure. 
Three stents were deployed in eight limbs (8.2%), and 
four stents were deployed in two limbs (2%). A Palmaz 
stent was generally chosen if the lesion was focal and 
the iliac artery was not tortuous, or if the needle 
puncture site was ipsilateral to the treated lesion. A 
Wallstent was generally chosen for longer lesions, 
particularly near the inguinal igament, for the treat- 
ment of tortuous iliac arteries, and for contralateral 
approaches tothe treated lesion. A combination of the 
two stents was generally placed to provide xtra length 
when a Wallstent did not completely cover the lesion. 
All patients were examined clinically before and 
after stent deployment. The decision to deploy the 
stent was made in concert by the staff vascular surgeon 
and the intervcntional radiologist. Before stent de- 
ployment all patients received 3000 units of heparin 
by intraarterial injection. Iliac artery stent deploy- 
ment was performed in 67 limbs (68.4%) during the 
initial arteriographic examination. Stent deployment 
was chosen in advance for some occlusions and other 
eccentric-looking stenoses in the other 31 treated 
limbs (31.6%). Primary stenting was performed in 72 
limbs (73.5 %), whereas the decision for stent deploy- 
ment in the other 26 limbs (26.5%) was made as a 
consequence ofa marginal result after balloon angio- 
plasty. Twenty-four 24 contralateral limbs (24.5%) 
were treated, and two limbs (2.0%) were treated in 
serial fashion on different dates. Simultaneous de- 
ployment of common iliac artery stents was done in 
five cases (5.1%). Technical success was defined as a 
systolic pressure gradient less than 5 mm Hg across 
the treated lesion after the procedure. All patients 
who were not already hospitalized were admitted for 
observation for 24 hours without a heparin drip. 
Aspirin (81 mg) was administered on the day ofstent 
placement and thereafter on a daily regimen. 
Iliac artery patency was assessed irectly at the 
latest follow-up with arteriographic examination i
17 limbs (17.3%) or indirectly by the criteria outlined 
by Rutherford and BeckeP 6 in 81 limbs (82.7%). All 
procedure-related and late (>30 days) complications, 
as well as adjunctive maneuvers equired to improve 
on a complication, were tabulated. Stented iliac artery 
cumulative primary patency and foot salvage rates 
were calculated with life-table analysis. The log-rank 
test was used to evaluate differences in stratified life 
tables. A stepwise logistic regression model was used 
to assess factors that affected early and late complica- 
tions, stented iliac artery primary patency rates, and 
foot salvage rates. Statistical significance was assumed 
ifp was less than 0.05. 
JOURNAL OF VASCULAR SURGERY 
Volume 24, Number 4 Ballard et al. 547 
RESULTS 
There were six initial treatment failures (6.1%). 
Three of these failures were acute ipsilateral iliac 
artery occlusion as a result of dissection, all of which 
were salvaged by the deployment of an additional 
stent. One ruptured iliac artery could not be salvaged 
with an additional stent and required resection and 
replacement with an interposition polytetrafluoro- 
ethylene graft. One episode of cholesterol emboli to a 
patent reversed saphenous vein femoropopliteal r- 
tery bypass graft required operative thrombectomy to 
reestablish graft patency. In the other initial treatment 
failure, stent infection necessitated resection of the 
stented common and external iliac arteries. This 
complication led to serious patient morbidity, includ- 
ing an ipsilateral bove-knee amputation, asdescribed 
in detail elsewhere. 17
Seven iliac artery dissections (7.1%) that caused a
hemodynamically significant stenosis, but not occlu- 
sion, were corrected by deployment of an additional 
stent during the procedure. Three other dissections 
(3.1%) received no treatment because the completion 
arteriogram demonstrated a widely patent iliac artery 
without a significant systolic pressure gradient 
(< 5 mm Hg). Other procedure-related complications 
included one external i iac artery rupture, which was 
treated successfully with balloon tamponade; one 
episode of intimal fracture and distal embolization, 
which was corrected by deployment of an additional 
stent and a 2-day infusion of urokinase; and one 
Palmaz stent embolization, which was retrieved per- 
cutaneously without further complication. 
Thus procedure-related complications occurred 
in 19 limbs ( 19.4% ). Endovascular djunctive maneu- 
vers as described above, however, rescued the proce- 
dure in 13 limbs (13.3%), and three complications 
(iliac artery dissection; 3.1%) required no treatment. 
Therefore, initial technical success was achieved in 95 
of 98 limbs (96.9%), with the need for endovascular 
adjuncts in 13 limbs. The mean ABI after the proce- 
dure was 0.81, with a mean improvement of 0.46 
(p < 0.000001, paired ttest). In 28 limbs (28.6%) the 
ABI after the procedure was >_0.90. 
The late complication (> 30 days) ofipsilateral iliac 
artery thrombosis developed in 10 limbs (10.2%) at a 
mean of 17.5 months (range, 6 to 25 months). No 
other late complications were directly related to the 
stented iliac artery. One patient sought medical atten- 
tion with reocclusion of the previously stented right 
common and external i iac arteries and new occlusion 
of the ipsilateral common femoral artery. Iliac artery 
patency was restored by a 24-hour infusion of urold- 
nase, restenting of the proximal common iliac artery, 
reexpansion of the external iliac artery stent, and 
primary stent deployment in the common femoral 
artery position. In another patient, a24-hour infusion 
of urokinase uncovered a severe ipsilateral external 
iliac artery stenosis distal to a previously deployed 
common iliac artery stent. Iliac artery patency was 
restored by balloon angioplasty. On e other iliac artery 
thrombosis was restored to patcncy by uncovering 
(with a 44-hour infusion of uroldnase) and treating 
(with an additional overlapping stent) a 95% stenosis 
just proximal to a previously deployed external i iac 
artery stent. Seven patients received no treatment for 
late iliac artery thrombosis. 
During a mean follow-up period of 16 months 
(range, 1 to 42 months), symptoms abated or minor 
tissue loss healed in 76 limbs (77.6%). A sustained 
improvement in the ABI was documented atthe time 
of follow-up in 72 of these limbs. The mean ABI was 
0.85, with a mean improvement of 0.50 from the 
preoperative measurement (p< 0.000001, paired 
t test). A follow-up ABI was not recorded in four of 
these 76 limbs. Follow-up symptoms, as well as the 
ABI, were unchanged in five limbs (5.1%). In addi- 
tion, there were seven major leg amputations (7.1%), 
and seven late patient deaths (10 limbs, 10.2%) from 
stroke (two patients), myocardial infarction (four 
patients), or metastatic ancer (one patient). No 
patient was lost to follow-up. 
The stcnted iliac artery cumulative primary pa- 
tency rate at 12 months was 87.6% (standard error 
[SE], 4%). By 18 months, however, the primary 
patcncy rate decreased to 61.9% (SE, 7%), and at 24 
months itwas 55.3% (SE, 9%). The results are listed in 
Table I and illustrated in Fig. 1. The stented iliac 
artery cumulative primary patency rate was affected 
by the position of the stent deployed within the iliac 
arterial system (p = 0.03, log-rank), by the patcncy 
status of the ipsilateral superficial femoral artery or 
equivalent bypass (p = 0.03, log-rank), and by the 
quality of the tibial vessel runoff below the popliteal 
artery (p < 0.000001, log-rank). This correlation is 
illustrated in Figs. 2 through 4. The stented iliac 
artery cumulative primary patency rate was not sig- 
nificantly affected by the type of stent that was 
deployed (p= 0.07, log-rank), by the presenting 
symptom (p= 0.23, log-rank), or by the occlusive 
status of the lilac artery segment before the treatment, 
that is, stenotic or occluded (p = 0.37, log-rank). 
The cumulative primary foot salvage rates were 
96.7% (SE, 2%), 85.1% (SE, 6%), and 76.1% (SE, 10%) 
at 12, 18, and 24 months, respectively. The results are 
listed in Table II and illustrated in Fig. 5. Life-table 
statistics for foot salvage were not significantly af- 
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Fig. 1. Life-table analysis ofstented iliac artery cumulative primary patency rate. SE <10% for 
plot through 30 months. 
Table I. Stented iliac artery primary patency rates 
Iliac arteries withdrawn due to 
Interval Iliac arteries Interval patency 
start time entering interval Terminal events Duration Loss to follow-up Death rate 
Cumulative 
patency rate SE 
0mo 98 2 3 0 2 
6 mo 91 3 20 0 2 
12mo 66 4 17 0 1 
18mo 44 10 19 0 1 
24mo 14 1 8 0 1 
30 mo 4 1 2 0 0 
36 mo 1 0 0 0 0 
42 mo 1 0 1 0 0 
0.9791 97.9 0.0147 
0.9625 94.2 0.0251 
0.9298 87.6 0.0395 
0.7059 61.9 0.0739 
0.8947 55.3 0.0904 
0.6667 36.9 0.1622 
1.000 36.9 0.1622 
1.000 36.9 0.1622 
fected by the patency status of the iliac artery before 
treatment (p = 0.98, log-rank), by the position of the 
deployed iliac artery stent (p -- 0.83, log-rank), by the 
patency status of the ipsilateral superficial femoral 
artery or equivalent bypass (p -- 0.15, log-rank), or by 
the quality of the tibia[ vessel runoff (p= 0.25, 
log-rank). The cumulative primary foot salvage rate, 
however, was influenced by the presenting symptom 
(p< 0.000001, log-rank). Amputations occurred 
only in limbs that had limb-threatening ischemia. 
Superficial femoral artery occlusion (p = 0.01 ) or 
stenosis (p= 0.03), and two-vessel (p--0.02) or 
one-vessel (p < 0.000001) tibial artery runoff were 
the variables that were demonstrated by stepwise 
logistic regression analysis to significantly affect 
stented iliac artery cumulative primary patency rates. 
The position of the deployed stent within the iliac 
system was not found to be significant by regression 
analysis with regard to the cumulative primary pa- 
tency rate. The regression analysis demonstrated 
pedal gangrene (p < 0.000001) to be a significant 
factor for limb loss. However, no other variable or 
combination of variables had an impact on the preva- 
lence of limb loss. 
Stepwise logistic regression analysis also demon- 
strated that pedal gangrene (p = 0.01) or the combi- 
nation of superficial femoral artery occlusion with 
single-vessel tibial runoff (p= 0.01) were the only 
variables that were significantly associated with a 
procedure-related complication. In addition, the late 
complication rate of iliac artery thrombosis was sig- 
nificantly impacted by a history of femoropopliteal 
bypass (p = 0.01) or by pedal gangrene as the pre- 
senting symptom (p < 0.000001). 
DISCUSSION 
Deployment of a metallic stent into a stenotic or 
occluded segment of an iliac artery is clearly feasible; 
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Fig. 2. Life-table analysis of stented iliac artery cumulative primary patency rate stratified for 
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Fig. 3. Life-table analysis of stented iliac artery cumulative primary patency rate stratified for 
ipsilateral pretreatment superficial femoral artery or equivalent bypass patency status. SE < 10% for 
"patent" plot through 30 months; however, SE >10% after 12 months for "stenotic" plot and 
after 18 months for "occluded" plot. 
however, the procedure augments vessel thromboge- 
nicity and leads to myointimal hyperplasia. 18Unex- 
pected procedure-related complications are not infre- 
quent, 2q5 but early failure and complication rates as 
reported are not complete. In some reports, cases are 
excluded from analysis, serial complications in a 
stented iliac arterial segment are only counted once, 
or complications are not counted at all. 3-a'7'8'1°'15 
Therefore, a percentage of some initial excellent 
technical success rates (range, 95% to 100%) are a 
result of adjunctive ndovascular maneuvers. 
Reported short-term and long-term clinical out- 
comes are usually favorable, 21~ but standard life-table 
analysis of stented iliac artery patency rates is rarely 
reported. >s Available data suggest that the 24-month 
stented iliac artery cumulative primary patency rate 
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Table II. Primary foot salvage rates 
Limbs withdrawn due to: 
Interval Limbs entering Interval salvage Cumulative foot 
start time interval Limb loss Duration Loss to follow-up Death rate salvage rate SE 
0 mo 98 1 4 0 2 0.9895 98.9 0.0105 
6 mo 91 1 22 0 2 0.9873 97.7 0.0162 
12 mo 66 0 21 0 1 1.0000 97.7 0.0162 
18 mo 44 4 25 0 1 0.8710 85.1 0.0605 
24 mo 14 1 8 0 1 0.8947 76.1 O. 1005 
30 mo 4 0 3 0 0 1.0000 76.1 0.1005 
36 mo 1 0 0 0 0 1.0000 76.1 0.1005 
42 mo 1 0 1 0 0 1.0000 76.1 0.1005 
ranges from 74% to 86.5%, with SEs greater than 10% 
in all reports except one, which did not list SEs. 2-s 
Long-term stented iliac artery cumulative primary 
patency rates of 54% (SE, 7.9%) and 63% (SE, 10%) 
have been documented at60 months. 2,s Despite an 
initial technical success rate of 96.9%, the stented iliac 
artery cumulative primary patency rate at 24 months 
in our experience was only 55.3% (SE, 9%). This value, 
which is lower than that published elsewhere, reflects 
a tabulated outcome for allcases, analysis by intention 
to treat, and a strict definition of treatment failure or 
complication. 
Adverse patient selection in this series also may 
have contributed to the observed decrease in the 
stented iliac artery cumulative primary patency rate. 
Eight patients (11.1%; eight limbs, 8.2%) were con- 
sidered to be prohibitive surgical risks as a result of 
debilitating comorbid medical problems. In addition, 
13 limbs (13.3%) in 12 patients (16.7%) had superfi- 
cial femoral artery occlusion with single-vessel tibia] 
artery runoff. Two of the above 20 patients (two 
limbs) had both problems. Therefore, this experience 
does include some patients who were not candidates 
for aortoiliac reconstruction or distal revasculariza- 
tions and some patients who were not ideal candidates 
for iliac artery stent deployment. None of the high 
surgical risk patients, however, and only one patient 
(one limb) who had superficial femoral artery occlu- 
sion and single-vessel tibial artery runoff had late 
stented iliac artery thrombosis. Regression analysis 
also demonstrated that the patients' demographic 
factors did not contribute to stent failure, as did poor 
superficial femoral and tibial artery outflow. 
We observed a highly statistically significant de- 
crease in the stented iliac artery cumulative primary 
patency rate when the superficial femoral artery was 
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Fig. 5. Life-table analysis of cumulative foot salvage. SE <10% for plot through 42 months. 
stenotic or occluded and the limb had one-vessel or 
two-vessel tibial artery runoff. Poor infrainguinal 
runoff has been noted to adversely affect long-term 
aortofcmoral bypass graft patency rates, as well as 
stented iliac artery patency rates. 6'12,19 A contributing 
factor to this reduction in the patency rates of iliac 
artery stenting procedures may bc the presence of 
common or deep femoral artery stenosis that ordi- 
narily would be corrected uring an open procedure. 
Profundaplasty performed in conjunction with 
aortofemoral bypass can help to compensate for 
deteriorated outflow and has been shown to be 
important for prolonged aortofemoral bypass graft 
patency. ]921 Open femoral endartercctomy, pro- 
fundaplasty, or both in conjunction with intraopera- 
tive iliac artery stent deployment may be advisable for 
selected patients who have iliac artery lesions that are 
amenable to stent placement and associated severe 
common or dccp femoral artery atherosclerotic dis- 
ease. This procedure could be accomplished under a 
local anesthetic for high surgical risk patients. 
It is somewhat surprising that the stented iliac 
artery cumulative primary patency rate was not af- 
fected by the number of stents deployed or by 
whether the treated iliac artery was stenotic or oc- 
cluded. This observation, however, has been corrobo- 
rated by other investigators. 2-4'6'12 Similarly, patient 
age, hypertension, coronary artery disease, hypercho- 
lesterolemia, nd presenting symptom did not factor 
into stented iliac artery patcncy rates. Diabetes did 
not negatively affect stented iliac artery cumulative 
primary patency rates as might be expected because 
superficial femoral and tibioperoncal rtery occlusive 
disease did significantly affect he patency rates. This 
finding also has been demonstrated in some, but not 
all, previous reports. 2&6'12 
Diabetes also did not significantly affect he preva- 
lence of limb loss. The presenting symptom, however, 
particularly pedal gangrene, was important and di- 
rectly correlated with limb loss. All of the amputations 
in this series occurred in patients who sought medical 
attention with limb-threatening ischemia. Two of 
seven limbs (28.6%) that had major amputations also 
had superficial femoral artery occlusion and single- 
vessel tibial runoff, but none of these amputations 
occurred in patients who were considered to be 
prohibitive surgical risks. Thus nearly one third of the 
major leg amputations occurred in patients who may 
have been considered candidates for primary ampu- 
tation. Improved inflow provided by iliac artery stent 
deployment , however, afforded six of seven patients a 
below-lmee amputation i stead of an above-knee 
amputation. 
It is not likely that stented iliac artery thrombosis 
leads directly to limb loss. The thrombosed or rup- 
tured stented iliac artcry, however, may be irreparable. 
In our experience, operative balloon catheter throm- 
bectomy has a low yield unless the stent has been 
carefully tapered to abut the arterial wall. Aortoiliac 
endarterectomy is precluded, and pulling the stent 
out of the artery risks further intimal damage. The 
dense inflammatory eaction, particularly surround- 
ing an infected, stented artery, contributes greatly to 
the complexity of a direct operative procedure. 17If a 
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direct approach to a stented iliac artery is required, it 
should be remembered that the potential ly exposed 
ends o f  the stent, especially the Wallstent, are sharp. 
Inadvertent  puncture exposes the surgeon to blood- 
borne pathogens. 
There are several better t reatment opt ions that can 
be used after stent hrombosis.  Successful thromboly-  
sis will potential ly uncover new treatable lesions and 
allow for addit ional bal loon angioplasty, stent deploy- 
ment,  or both. Previously deployed stents also can be 
reexpanded. The conventional aortofemoral  bypass 
procedure,  with the origin and destination o f  the graft 
placed at remote sites to avoid the traumatized vessel, 
is still an option. Extraanatomic bypass may be pref- 
erable in high-risk patients or to avoid an infected 
field. Less commonly,  segmental resection ofa  stented 
iliac artery with graft replacement will be performed.  
This potential ly compl icated approach wi thout  graft 
replacement,  however, is the only opt ion in the case o f  
stent infection. 17 
Dur ing the per iod o f  this study, 1992 to 1995, our 
approach to stentAng atherosclerotic arterial disease 
was evolving. Patients who had common iliac artery 
occlusive disease or eccentric stenoses, patent super- 
ficial femoral arteries, and three-vessel tibial runof fare 
ideal candidates to undergo a stent procedure.  I f  the 
above patient has severe common and/or  deep femo- 
ral artery occlusive disease, a combined operative and 
endovascular procedure is advisable. Caut ion with 
severe isolated external i iac artery occlusive disease is 
wise because the stented external iliac artery patency 
rate appears to be inferior to that o f  more proximally 
deployed iliac artery stents. A thoughtful ly selected 
outf low procedure can be expected to enhance the 
stented iliac artery cumulative pr imary patency rate, 
particularly in patients who have superficial femoral 
artery occlusion, one-vessel tibial artery runoff,  or 
both. 
CONCLUSIONS 
Iliac artery stent deployment  is an invasive proce- 
dure that has associated l imb-threatening and life- 
threatening complications. The stented iliac artery 
cumulative pr imary patency rate is more directly 
related to infrainguinal arterial occlusive disease than 
to the nature o f  the treated iliac artery, that is, stenosis 
versus occlusion. Patient demographic  factors corre- 
late better with the prevalence of  l imb loss than with 
the incidence o f  stent failure. Randomizat ion o f  this 
procedure with operative aortoil iac artery reconstruc- 
t ion is needed to improve pat ient selection and to 
guide the future t reatment of  severe iliac artery 
occlusive disease. 
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D ISCUSSION 
Dr. Kaj Johansen (Seattle, Wash.). This is an important 
and perhaps even a landmark contribution. As far as I can 
tell, it is the first large-scale series to have adequatc fol- 
low-up and proper data collation ("intent-to-treat", proper 
definition, and tabulation of individual outcome points) for 
what is widely presumed to be the "best-case" scenario for 
percutaneous stenting--the iliac artery. The authors dem- 
onstrate that technical success results in 98% of such 
patients, that procedure-related complications will occur in 
one fifth of the patients (but that most of these can be 
treated "on the spot"), and that the cumulative primary 
patency rate declines to 50% at 2 years. The article is even 
more useful because the authors document, with the proper 
statistical methods, the factors that have an impact on 
long-term outcome (external i iac artery stenting, outflow 
obstruction caused either by superficial femoral or by tibial 
artery occlusion) and those that do not (cardiovascular 
comorbidity, diabetes, presenting symptoms, number of 
stents deployed, the presence of an early complication). 
There is no doubt that a role for the endovascular 
reconstruction f the iliac artery exists; are there ways that 
we can optimize this technique? I have the following series 
of questions designed to discern how we can better select 
candidates for this procedure, or better accomplish it. First, 
technical "success" in this study was defined as a <10 mm 
Hg pressure gradient, or <25% residual stenosis. We know 
from other data (for example, percutaneous coronary artery 
angioplasty) that the lower the residual stenosis i , the better 
the long-term results arc. Did you correlate outcome with 
the initial technical result? You showed that whether it was 
a stenosis or an occlusion that was being stented didn't 
matter: what about the length of the diseased segment? 
Second, members of this Society and others have proved 
the benefits of various antiplatelet or anticoagulant agents 
for at least early patency of vascular graft reconstruction. 
What about he use ofheparin, aspirin, dextran, or warfarin 
in the periprocedural period for iliac artery stents? 
Other adjunctive interventions are important as well. 
We would ncver perform an aortofemoral bypass grafting 
procedure without at least assuring ood profunda outflow. 
What was the impact of infrainguinal vascular reconstruc- 
tion on the long-term patency rates ofiliac artery stenting 
procedures? 
Fourth, during this period of time you obviously had a 
series of people who didn't undergo illac artery stenting, but 
instead underwent some form of operative intervention-- 
usually bypass or endarterectomy. How did that simulta- 
neous group of patients, a sort of surgical control group to 
your series presented today, farc during the same follow-up? 
You have shown in unimpeachable fashion, as far as I 'm 
concerned, which patients are at risk for early or late 
complications of iliac artery stenting. Has this experience 
caused you and your interventional radiology colleagues to 
alter your decisionmaking algorithm when confronted with 
a patient in whom iliac artery stent deployment is an option? 
Dr. Jeffrey L. Ballard. We did indeed measure gradi- 
ents after stent deployment. Successful deployment re- 
quired the residual stenosis to be less than 25%. However, I 
do not have the data right now that would tell you what 
happened to patients who had a 20% residual stenosis versus 
somebody who had zero residual stenosis. 
We did not measure lengths of occlusions because I was 
ultimately trying to compare stent deployment with a 
surgical procedure. The occlusion length is inconsequential 
for bypass grafting procedures. 
In our early experience, patients were admitted over- 
night. A few were given a nontherapeutic heparin drip. Most 
patients were discharged the following day. Once wegot  
more comfortable with deployment of iliac artery stents, 
they were performed as outpatient procedures. The patients 
are recommended to take one baby aspirin (81 nag) every 
day. We don't use any other adjuncts, such as warfarin or 
dextran. 
During the same period of time there were 55 aorto- 
bifemoral bypasses, 12 axillobifemoral bypasses, 10 femo- 
rofemoral bypasses, and five or six iliofemoral bypass pro- 
cedures performed. Those patients are currently being 
compared with this group regarding complication rate, 
average length of stay, and cost analysis. Also, I did not look 
specifically at subsequent infrainguinal reconstruction. 
On the basis of this experience we are more likely to 
treat common lilac artery occlusive disease than external 
iliac artery occlusive disease. We are also more likely to 
recommend surgery if more than one stent is required. 
When I get a phone call that says, "Hey, I can fix this with 
five stents," I say, "Well, that would be very nice, but don't 
do it." If  one stent is required and the lesion is in the 
common iliac artery, I think that is very acceptable treat- 
ment at this time. 
We are more likely to compromise a little bit on that 
algorithm in a patient who has severe prohibitive surgical 
risks. In a few patients in this series we pushed the limit a 
little bit, hoping to get a reasonable 1-year or 2-year patency 
rate. 
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Dr. Ronald L. Dalman (Stanford, Calif.). We have a 
limited experience with stent graft exclusion of iliac aneu- 
rysms, and I think in the last year we have performed less 
than a dozen or so, but we've had two patients in whom 
severe iliofemoral venous thrombosis and phlegmasia de- 
veloped after stent graft exclusion of iliac aneurysms. I 
wonder whether you can comment on that. 
Dr. Ballard. It's actually not surprising that that might 
be the case because of the inflammatory reaction that 
surrounds even a normal artery that's tented. The inflam- 
matory reaction is intense and results in a dense fibrotic 
reaction around the artery. Maybe that process, in conjunc- 
tion with the thrombosed aneurysm, was enough to cause 
venous tasis. 
Dr. Samuel E. Wilson (Orange, Calif.). The ABI of 
0.34 in your patients uggests quite severe disease and 
multiple levels of occlusion. One of the great advantages of
lilac angioplasty is that it can allow you to perform a lesser 
distal procedure, such as performing a femorofemoral 
bypass or establishing inflow for a femoropopliteal bypass 
procedure in a patient who is too great a risk for an 
abdominal procedure. In how many patients did a proximal 
stenting procedure allow you to perform subsequent op- 
erations that would ~ot have been possible previously 
simply because the patient would not have been fit for an 
aortofemoral bypass procedure? 
Secondly, an important morbid factor that we don't 
count in evaluating percutaneous procedures i  the number 
of repeat procedures. Can you give an estimate of how many 
subsequent angioplasty procedures were required? 
Dr. Ballard. I agree with those comments. We are 
currently looking at the group of patients that you asked 
about first to try to put all that together. We have a very 
combined and open approach to these cases. None of these 
cases are done by a unilateral approach. 
I don't know how many patients had an inflow proce- 
dure and then a subsequent outflow procedure within a very 
short period of time, but that's data that I 'm currently 
gathering. 
Dr. Michael J. Sise (San Diego, Calif.). Did you look at 
patient satisfaction? When patients suffer ecurrent stenosis, 
they frequently endure months of symptoms before they 
undergo repeat angioplasty. In the past, we considered 
aortofemoral bypass as the gold standard for inflow proce- 
dures. Now it has almost become a"golden oldie" in many 
ways. 
Your drop-offat 12 months is very significant. We have 
a large group of patients who we are placing in an "inter- 
ventional limbo:" angioplasty, stent, restent, maybe afemo- 
rofemoral bypass, when that group of patients would have 
been better served with a well-planned, well-performed 
aortofemoral bypass, which has durable, long-term results 
with one intervention, one hospitalization. 
I strongly recommend that performing an aortofemo- 
ral bypass procedure is not a sign of failure. With angio- 
plasty, we, the vascular surgery community, had the task 
of defining outcome. Our interventional colleagues are 
procedure-specific. We must apply that same long-term 
patient outcome study technique that we used with an- 
gioplasty to the use of stents. I congratulate you on a very 
thoughtful paper. 
Dr. Ballard. We didn't specifically ook at psychological 
outcome analysis. One anecdotal case is a lady who refused 
an aortobifemoral bypass because it was going to conflict 
with her work schedule. We told her about this other 
option, and she thought it was the greatest thing since sliced 
bread. She came in for 24 hours, got her common iliac 
artery stented open, the rest pain went away, and she had a 
foot pulse. 
Eighteen months later she returned after having 6 
months of rest pain, lilac artery thrombosis, and gangrene of 
her toe. I said, "You really ought to have a bypass," and she 
said, "Absolutely not. I want you to do the same thing you 
did to me the last time." So she came in, got thrombolysis, 
and more stents were placed. This is the lady who ended up 
with a stent infection. 
So I agree. I think that a lot of these patients are served 
quite well with a standard aortobifemoral bypass, and 
enough with this gadgetry. 
Dr. Steven P. Murray (San Antonio, Texas). It was 
good to hear an analysis of interventional endovascular 
procedures judged on the level playing field of '  'intention to 
treat." Likewise, close prospective follow-up data are re- 
freshing. 
I do have a question about the percentage of patients 
who had claudication being subjected to diagnostic angiog- 
raphy. It appears that this group comprised 50% of the total 
as opposed to the 15% to 20% that I would normally 
anticipate being sent for angiography. If this true, did you 
then separate out, on the basis of indication for study, those 
complications that occurred? For instance, an amputation 
that results from angiographic and interventional tech- 
niques in someone who has a black toe is not the same as an 
amputation in somebody who has one-half to one block 
claudication. 
Lastly, in the December 1995 issue of Journal of 
Vascular Surgery, Dr. Queral of Maryland reports a tech- 
nique of retrograde iliofemoral endarterectomy that was 
facilitated by balloon angioplasty (J Vasc Surg 1995;22: 
742-50). This technique lends support o Dr. Schneider's 
proposal of a clinical and noninvasive laboratory work-up 
only, before operative intervention, on-table diagnostic 
angiography, and potentially therapeutic endovascular in- 
tervention. For instance, a common lilac and external i iac 
artery, once identified, could be dealt with by ballooning 
and stenting the common iliac artery and could be followed 
by extraction endarterectomy of the external iliac artery 
after ballooning to overstretch the artery. Would you 
comment on this, please? 
Dr. Ballard. We stratified the analysis for the presenting 
symptom, and there was no statistical significance between 
the presenting symptom and the patency rate. There is a 
clear difference, though, in the amputation rate. Amputa- 
tions were performed only in those patients who had 
limb-threatening ischemia. None of the patients who had 
claudication underwent an amputation, and the patient had 
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to be very severely disabled before we would consider any 
kind of invasive treatment. 
Dr. Gerald S. Treiman (Sacramento, Calif.). You 
treated apatient for distal embolization with urokinase. We 
have found urokinase to be ineffective for plaque emboli, 
and we now rarely use it for embolization after percutaneous 
transluminal angioplasty. How successful has urokinase 
been in your experience for this complication? 
Dr. Ballard. There was only one patient who had distal 
embolization. That was one of our early cases, and treat- 
ment with urokinase seemed to be appropriate. Amazingly 
enough, the patient improved. We have had very few cases 
of embolization with any of these interventions. 
Dr. D. Preston Flanigan (Orange, Calif. ). Your fall-off 
in patency rates between 12 or 18 months in the superficial 
femoral artery occlusion group was pretty impressive. The 
curve with your tibial artery analysis looked fairly identical. 
I 'm not sure how to interpret that. 
Is the effect in the tlbial group related to the superficial 
femoral artery occlusion, or did you control for superficial 
femoral artery occlusion when you analyzed the tibial artery 
runofP. 
Dr. Ballard. Superficial femoral artery occlusion and 
single-vessel tibial runoff independently and negatively 
affected the life table. Each factor was found to be highly 
statistically significant by regression analysis. 
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